Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Enlivex ( (ENLV) ) has issued an announcement.
On January 23, 2026, Enlivex Therapeutics announced it has begun the process of voluntarily delisting its ordinary shares from the Tel Aviv Stock Exchange, with trading on the TASE expected to end on April 23, 2026 and the delisting to become effective around April 26, 2026. The company’s shares will continue to trade on the Nasdaq Capital Market under the ticker ENLV, and all shares currently traded in Tel Aviv can be transferred to Nasdaq. Enlivex’s board approved the move to concentrate trading exclusively in the U.S., citing the desire to operate under a single regulatory regime, cut duplicative administrative costs tied to dual listing, potentially boost liquidity on Nasdaq, and focus investor and public relations efforts on the U.S. capital markets, a shift that could streamline operations and sharpen its visibility among U.S. biotech and digital-asset-focused investors.
The most recent analyst rating on (ENLV) stock is a Hold with a $0.96 price target. To see the full list of analyst forecasts on Enlivex stock, see the ENLV Stock Forecast page.
Spark’s Take on ENLV Stock
According to Spark, TipRanks’ AI Analyst, ENLV is a Neutral.
The score is primarily constrained by weak financial performance (no revenue, ongoing losses, and negative free cash flow), partially offset by low leverage on the balance sheet. Technicals are mixed with a short-term bounce but a broader downtrend, and valuation is not supportive given negative earnings and no dividend yield.
To see Spark’s full report on ENLV stock, click here.
More about Enlivex
Enlivex Therapeutics Ltd. is a clinical-stage biotechnology company specializing in macrophage reprogramming immunotherapy, currently focused on the late-stage clinical development of Allocetra™, a novel therapy targeting osteoarthritis, a highly prevalent and disabling joint disease with significant unmet medical need. The Israel-based company is also notable for operating a digital asset treasury strategy centered on the RAIN token as its primary treasury reserve asset, aiming to provide investors with exposure to this form of digital capital.
Average Trading Volume: 4,036,702
Technical Sentiment Signal: Sell
Current Market Cap: $232.6M
For a thorough assessment of ENLV stock, go to TipRanks’ Stock Analysis page.